Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology and prognosis of childhood lupus nephritis in the Afro-descendant population of the French Overseas Departments of America.

BMC nephrology·2026
Same author

A systematic review of short-term outcomes in patients with anti-factor H associated atypical HUS managed with plasma exchanges versus eculizumab.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Children born to mothers receiving chronic dialysis, a national French cohort (2013-2021).

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Antimeningococcal Protection in Patients Receiving Terminal Complement Inhibitors.

Kidney international reports·2026
Same author

Don't think that combined liver-kidney transplant can solve everything in primary hyperoxaluria type 1!

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial.

BMJ open·2025

Related Experiment Video

Updated: Jun 8, 2026

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
09:34

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy

Published on: May 18, 2017

Plasmatherapy in atypical hemolytic uremic syndrome.

Chantal Loirat1, Arnaud Garnier, Anne-Laure Sellier-Leclerc

  • 1Assistance Publique-Hôpitaux de Paris, Pediatric Nephrology Department, Université Paris-Diderot, Hôpital Robert Debré, Paris, France. chantal.loirat@rdb.aphp.fr

Seminars in Thrombosis and Hemostasis
|September 25, 2010
PubMed
Summary

Plasmatherapy is the empirical first-line treatment for atypical hemolytic uremic syndrome (aHUS), with plasma exchanges being more effective than infusions for certain factor H mutations. Early and prophylactic treatment may prevent end-stage renal disease.

Related Experiment Videos

Last Updated: Jun 8, 2026

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy
09:34

Preparation of Plasma Membrane Vesicles from Bone Marrow Mesenchymal Stem Cells for Potential Cytoplasm Replacement Therapy

Published on: May 18, 2017

Area of Science:

  • Nephrology
  • Hematology
  • Immunology

Background:

  • Atypical hemolytic uremic syndrome (aHUS) is a rare, severe condition.
  • Plasmatherapy is the current empirical first-line treatment, but prospective data are limited.
  • Understanding the role of complement system mutations is key to treatment efficacy.

Purpose of the Study:

  • To review the current evidence for plasmatherapy in atypical hemolytic uremic syndrome.
  • To compare the efficacy of different plasmatherapy methods based on genetic mutations.
  • To discuss the long-term outcomes and future therapeutic directions for aHUS.

Main Methods:

  • Review of existing literature on plasmatherapy for aHUS.
  • Analysis of treatment outcomes based on specific genetic mutations (Factor H, Factor I, C3, Factor B, MCP).
  • Comparison of plasma infusions versus plasma exchanges.

Main Results:

  • Plasma exchanges are more effective than plasma infusions in aHUS patients with dysfunctional Factor H mutations.
  • Early and prophylactic plasmatherapy may be more effective in preventing end-stage renal disease than on-demand treatment.
  • Plasmatherapy efficacy is questionable in aHUS with membrane cofactor protein mutations and limited data exist for Factor I, C3, or Factor B mutations.

Conclusions:

  • Plasmatherapy is a crucial, albeit empirically used, treatment for aHUS, with varying efficacy depending on the underlying genetic defect.
  • Long-term prophylactic plasmatherapy shows promise in preserving renal function, but longer follow-up is needed.
  • Complement inhibitors represent a promising future therapeutic strategy for aHUS, potentially improving patient outcomes and quality of life.